Gluconic Acid

Identification

Name
Gluconic Acid
Accession Number
DB13180
Description

Commonly found in salts with sodium and calcium. Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 196.1553
Monoisotopic: 196.058302738
Chemical Formula
C6H12O7
Synonyms
  • D-Gluconic Acid
  • Dextronic acid
  • Maltonic acid
External IDs
  • E-574
  • INS no.574
  • INS-574
  • NSC-77381
  • Pentahydroxycaproic acid

Pharmacology

Indication

For use as part of electrolyte supplementation in total parenteral nutrition [FDA Label].

Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Used as part of electrolyte salts to maintain cation-anion balance in solutions.

Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Gluconic Acid.
AlfentanilThe therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Alfentanil.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Gluconic Acid.
AmiodaroneThe therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Amiodarone.
AmlodipineThe therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Amlodipine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Gluconic Acid.
BenzhydrocodoneThe therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Benzhydrocodone.
BenzthiazideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Gluconic Acid.
BepridilThe therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Bepridil.
BromotheophyllineThe risk or severity of adverse effects can be increased when Bromotheophylline is combined with Gluconic Acid.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Product Ingredients
IngredientUNIICASInChI Key
Sodium gluconateR6Q3791S76527-07-1UPMFZISCCZSDND-JJKGCWMISA-M
Active Moieties
NameKindUNIICASInChI Key
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Hyperlyte (multi-electrolyte Concentrate)Sodium gluconate (1.09 g) + Calcium acetate (440 mg) + Magnesium acetate (860 mg) + Potassium acetate (690 mg) + Potassium chloride (2.46 g) + Sodium acetate (2.72 g)LiquidIntravenousB. Braun Medical Inc.1998-09-042017-07-15Canada
Isolyte SSodium gluconate (0.5 g/100mL) + Magnesium chloride hexahydrate (0.03 g/100mL) + Potassium chloride (0.037 g/100mL) + Sodium acetate trihydrate (0.37 g/100mL) + Sodium chloride (0.53 g/100mL)Injection, solutionIntravenousB. Braun Medical Inc.1989-09-29Not applicableUs
Isolyte S (multi-electrolyte Injection)Sodium gluconate (500 mg) + Magnesium chloride (30 mg) + Potassium chloride (37 mg) + Sodium acetate (370 mg) + Sodium chloride (530 mg)SolutionIntravenousB. Braun Medical Inc.1992-12-31Not applicableCanada
Isolyte S in DextroseSodium gluconate (0.5 g/100mL) + D-glucose monohydrate (5 g/100mL) + Magnesium chloride hexahydrate (0.03 g/100mL) + Potassium chloride (0.037 g/100mL) + Sodium acetate trihydrate (0.37 g/100mL) + Sodium chloride (0.53 g/100mL)Injection, solutionIntravenousB. Braun Medical Inc.1993-08-092014-05-30Us
Isolyte S pH 7.4Sodium gluconate (0.5 g/100mL) + Magnesium chloride hexahydrate (0.03 g/100mL) + Monopotassium phosphate (0.00082 g/100mL) + Potassium chloride (0.037 g/100mL) + Sodium acetate trihydrate (0.37 g/100mL) + Sodium chloride (0.53 g/100mL) + Sodium phosphate, dibasic, unspecified form (0.012 g/100mL)Injection, solutionIntravenousB. Braun Medical Inc.1989-09-29Not applicableUs
Isolyte S Ph 7.4 (multi-electrolyte Injection)Sodium gluconate (500 mg) + Magnesium chloride (30 mg) + Monopotassium phosphate (820 mcg) + Potassium chloride (37 mg) + Sodium acetate (370 mg) + Sodium chloride (530 mg) + Sodium phosphate, dibasic (12 mg)SolutionIntravenousB. Braun Medical Inc.1996-09-10Not applicableCanada
Isolyte S With 5% Dextrose InjSodium gluconate (500 mg) + Dextrose, unspecified form (5 g) + Magnesium chloride (30 mg) + Potassium chloride (37 mg) + Sodium acetate (370 mg) + Sodium chloride (530 mg)SolutionIntravenousB. Braun Medical Inc.1996-09-102018-12-12Canada
IsoplateSodium gluconate (0.5 g/100mL) + Magnesium chloride hexahydrate (0.03 g/100mL) + Monopotassium phosphate (0.00082 g/100mL) + Potassium chloride (0.037 g/100mL) + Sodium acetate trihydrate (0.37 g/100mL) + Sodium chloride (0.53 g/100mL) + Sodium phosphate, dibasic, unspecified form (0.012 g/100mL)SolutionIntravenousB. Braun Medical Inc.2013-03-052013-04-19Us
IsoplateSodium gluconate (0.5 g/100mL) + Magnesium chloride hexahydrate (0.03 g/100mL) + Monopotassium phosphate (0.00082 g/100mL) + Potassium chloride (0.037 g/100mL) + Sodium acetate trihydrate (0.37 g/100mL) + Sodium chloride (0.53 g/100mL) + Sodium phosphate, dibasic, unspecified form (0.008 g/100mL)SolutionIntravenousTerumo BCT Ltd.2013-03-05Not applicableUs
LypholyteSodium gluconate (1.1 g) + Calcium acetate (440 mg) + Magnesium acetate (860 mg) + Potassium acetate (690 mg) + Potassium chloride (2.5 g) + Sodium acetate (2.7 g)SolutionIntravenousPartners Health Care, Inc.1996-08-142008-01-10Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
NutrilyteSodium gluconate (55 mg/1mL) + Calcium acetate (22 mg/1mL) + Magnesium acetate (43 mg/1mL) + Potassium acetate (34.5 mg/1mL) + Potassium chloride (125 mg/1mL) + Sodium acetate trihydrate (135 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302013-05-08Us

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar acids and derivatives
Alternative Parents
Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Hydroxy fatty acids / Beta hydroxy acids and derivatives / Monosaccharides / Alpha hydroxy acids and derivatives / Secondary alcohols / Polyols / Monocarboxylic acids and derivatives / Carboxylic acids
show 4 more
Substituents
Alcohol / Aliphatic acyclic compound / Alpha-hydroxy acid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Fatty acid / Fatty acyl / Gluconic_acid
show 11 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
gluconic acid (CHEBI:33198) / Uronic acids (C00257)

Chemical Identifiers

UNII
R4R8J0Q44B
CAS number
526-95-4
InChI Key
RGHNJXZEOKUKBD-SQOUGZDYSA-N
InChI
InChI=1S/C6H12O7/c7-1-2(8)3(9)4(10)5(11)6(12)13/h2-5,7-11H,1H2,(H,12,13)/t2-,3-,4+,5-/m1/s1
IUPAC Name
(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O

References

General References
Not Available
Human Metabolome Database
HMDB0000625
KEGG Compound
C00257
PubChem Compound
10690
PubChem Substance
347829282
ChemSpider
10240
ChEBI
33198
ChEMBL
CHEMBL464345
ZINC
ZINC000001531008
PharmGKB
PA449770
PDBe Ligand
GCO
Wikipedia
Gluconic_acid
PDB Entries
1bgg / 1xlf / 3o03 / 3oy8 / 3qke / 3t6c / 3twb / 4k2s / 4zlg / 6e9n

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentHypovolaemia1
3CompletedTreatmentAnaesthesia therapy1
3RecruitingTreatmentDelayed Graft Function / End Stage Kidney Disease / Kidney Transplant; Complications1
2Active Not RecruitingTreatmentAnterior Wall Myocardial Infarction1
2CompletedPreventionAcute Kidney Injury (AKI)1
2CompletedTreatmentNeoplasms, Brain1
2CompletedTreatmentRespiratory Distress Syndrome, Adult1
0CompletedDiagnosticHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravenous
LiquidIntravenous
Injection, solution, concentrateIntravenous
IrrigantIrrigation
Injection, solutionIntravenous
Powder, for solutionIrrigation; Topical
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility159.0 mg/mLALOGPS
logP-2.6ALOGPS
logP-3.4ChemAxon
logS-0.09ALOGPS
pKa (Strongest Acidic)3.39ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area138.45 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity38.27 m3·mol-1ChemAxon
Polarizability17.15 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0002-0932000000-202af87cea2d1f7184ab
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-005a-0920000000-2308d9356bc5bb01420e
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-014j-0950000000-61ab7adf15e353df4ba2
GC-MS Spectrum - GC-MS (6 TMS)GC-MSsplash10-0le9-1964000000-5eb7d6777170e1ad5fa0
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0002-0932000000-202af87cea2d1f7184ab
GC-MS Spectrum - GC-MSGC-MSsplash10-0le9-1964000000-5eb7d6777170e1ad5fa0
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0002-0931000000-b07fcc4ac1e6701d32c8
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0fr2-0930000000-181f7b697b591cf8080b
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-06vj-1900000000-78e4a5d92be678c068e4
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-03ds-5900000000-f5d8284baa473ce9d77f
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-014i-9500000000-7c5b20eef98d0e3d6cbb
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-0002-0900000000-b2632ca9154cc5e44438
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-002b-5900000000-4a3066f9dfd6653682fb
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-004i-9000000000-50f63dfd017a8380a47c
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-056r-9000000000-91ccf7c8949c1c9d852a
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-0a6r-9000000000-6e40f1cebd8b460016b3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0002-0900000000-b2632ca9154cc5e44438
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-002b-5900000000-cf9b480ac397acfebc71
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-004i-9000000000-eca61f6a9c0f1d06e84d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-056r-9000000000-91ccf7c8949c1c9d852a
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a6r-9000000000-6e40f1cebd8b460016b3
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Drug created on June 08, 2017 20:30 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates